

COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

WEDNESDAY, SEPTEMBER 18, 1968

U.S. SENATE,
MONOPOLY SUBCOMMITTEE OF THE
SELECT COMMITTEE ON SMALL BUSINESS,
Washington, D.C.

The subcommittee met, pursuant to recess, at 9:35 a.m., in room 318, Old Senate Office Building, Senator Gaylord Nelson (chairman of the subcommittee) presiding.

Present: Senators Nelson and Hatfield.

Also present: Benjamin Gordon, staff economist; James H. Grossman, minority counsel; Elaine C. Dye, research assistant; and William B. Cherkasky, legislative director, staff of Senator Nelson.

Senator NELSON. Our first witness this morning is Dr. Harvey Minchew, Acting Director, Bureau of Medicine, Food and Drug Administration.

Dr. Minchew, we are very pleased to have you here this morning. You may proceed to present your statement as you see fit.

STATEMENT OF DR. B. HARVEY MINCHEW, ACTING DIRECTOR, BUREAU OF MEDICINE, FOOD AND DRUG ADMINISTRATION; ACCOMPANIED BY DR. ROBERT S. McCLEERY, ACTING DEPUTY DIRECTOR, BUREAU OF MEDICINE, FDA; HARRY CHADDUCK, DEPUTY DIRECTOR, DIVISION OF MEDICAL ADVERTISING, BUREAU OF MEDICINE, FDA; WILLIAM W. GOODRICH, GENERAL COUNSEL, FDA; MORTON M. SCHNEIDER, ASSISTANT DIRECTOR, OFFICE OF LEGISLATIVE AND GOVERNMENTAL SERVICES, FDA; AND DR. ALAN SMITH, DEPUTY DIRECTOR, DIVISION OF ANTI-INFECTIVE DRUGS, BUREAU OF MEDICINE, FDA

Dr. MINCHEW. Mr. Chairman: I appreciate this opportunity of appearing before you this morning to discuss the marketing approval and the promotion of Vibramycin, Chas. A. Pfizer & Co.'s brand name for doxycycline. For the sake of brevity, with your permission, I will submit for the record a statement of my educational and professional background.

Senator NELSON. It will be printed in the record at this point.
(The biographical data follow:)

BIOGRAPHICAL SKETCH OF B. HARVEY MINCHEW, M.D.

Date of Birth: May 1, 1932.

Place of Birth: Waycross, Georgia.